Date

Presenter

4/4

坂本

4/11

4/18

Title

5/2

5/9

Year

Vol

Page

Blood

2023 140(23)2500-2513

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial

JAMA2017 318(6)557-566

Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized
JAMA Oncol
Clinical Trial

2023 e227605

一瀬

Molecular profiling of EBV associated diffuse large B-cell lymphoma

Leukemia

2023 37(3)安東

A neutrophil response linked to tumor control in immunotheray

Cell

2023

186 1448-1468

T cell immunotherapies engage neutorophils to eliminate tumor antigen escape variants

Cell

2023

186 1432-1447

Neutorophil-activating therapy for the treatment of cancer

Cancer cell2023

41 356-372

松本Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Blood

2023

児嶋

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase
Clin Oncl
II Trial

2023 41(2)327-335

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

Blood adv

2023 7(7)1130-1136

Nat med2022 28(2)325-332

Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Cancers(Basel)

2023 15(6)1839

Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab

Cancer2013 60(1)101-109

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

N Engl J med

2020 382(19)1811-1822

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Blood2020 136(6)657-668

加藤

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas

J Clin Oncol

2023 41(9)1684-1694

清水Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a SingleArm, Multicenter, Phase II Study
J Clin Oncol

2023

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy

Cancer Immuno

2017 66(7)877-890

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted
therapy

Clin Cancer Res

2012 18(6)1611-1618

糸永

RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia

Blood2023 141(10)1105-1118

佐藤UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Leukemia

2023 doi: 10.1038

s41375-023-01906-z.

クリクラ学生 Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
4/25

JournalAzithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation

蓬莱670-679

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised,
Lancet double-blind, placebo-controlled,2023 401(10388)
phase 3 trial1571-1583
5/16

5/23

古本

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Blood

2023 141(14)1666-1674

桐野

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

Leukemia

2020 34(5)1373-1382

Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a PhaseBlood
2 Study2017 130(1)Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)

Adv Hematol

2022 doi: 10.1155/2022/1182384

渡辺

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Blood adv

2023 doi:10.1182

宮﨑

MDS、AMLの診断と治療の変遷についての解説
Lancet2023 401(10388)

Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV

Diagnostics(Basel)

2022 12(3)Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Blood adv

2020 4(18)4442-4450

Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

Cancer Discov

2022 14(6)1449-1461

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a
クリクラ学生 randomised, double-blind, placebo-controlled, phase 3 trial
5/30

田口(留学報告)

6/6

一瀬
坂本

6/13

1838

1571-1583
713

加藤

清水
6/20

松本

安東
6/27

山田

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase
JCO II Trial

2023 Jan41(2)327-335

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
JAMA Oncol

2020 Jun

6(6)872-880

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma

2010 Aug363(7)

640-52

N Engl J Med

クリクラ学生
7/4

糸永児嶋

Nat Med.2023;29:422 N Engl J Med .DOI:10.1056 N Engl J Med.2022;388:1284 Nature .2022 ;603:934 Nat Med.2023;29:803 Transplant Cell Ther.2023 J Clim Oncol.2022 ;41:343
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

NEJM

2023

388 2338-2348

7/11

渡辺

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Lancet2008 371(9624)

1579-86

Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic
Ann Hematol
stem cell transplantation2023 102(6)Front Immunol

2022

Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence

Bone Marrow transplant

2021 56(10)2355-2366

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

J Clin Oncol

2023 41(15)2827-2842

N Engl J Med

2023 389(2)148-157

児嶋

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Lancet.2023 Jul 29;402(10399):373-385 J Clin Oncol.2023 Oct 1;41(28):4486-4496
J Clin Oncol.2023;41(10):1820-42 N Engl J Med.2021;385(3):228-238 Blood.2021;1388(22):2278-89

佐藤Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia

Leukemia

2023 37(4)765-775

Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia

Leukemia

2023 37(8)1638-48

Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research

Leukemia

2012 26(5)1091-1097

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresblood

2022 139(17)2666-2672

Multiparameter prediction of myeloid neoplastic risk

Nature Genetics

2023 55(9)1523-1530

Real-world data of long-term survival in patienwith T-cell lymphoma who underwent stem cell transplantation

Blood Cancer J 2023 Jun

13(1)

95

Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas

Acta Derm Venereol
2022 Mar102

adv00676.

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma

Clin Lymphoma Myeloma
2018 JanLeuk18(1)e85-e93

Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement

Cell

186(21)4528-4545

蓬莱
7/18

クリクラ学生桐野
7/25

1537-1547

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease

9/26 坂本一瀬
10/3 山田宮﨑
10/10 渡辺田口
11/7 桐野加藤
11/14 安東山田
11/21 児嶋糸永
11/28 蓬莱渡辺
12/5 佐藤松本
12/12 田口13959638Transplant Cell Ther.2023 Oct;29(10):622-631 J Clin Invest.2023 Aug 1;133(15)2023 Oct 12（敬称略)Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable
blood Residual2022
Diseasedec Negative140(sup2)
Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III Na
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Lancet Haematol 2023 jan

10(1)e24-e34

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute
Lymphoblastic Leukemia: Updated Results from a Phase II Studyblood2022 Nov

140(sup1)

8966-8968

Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial

cancer cell2023 Oct41(10)

1705-1716

Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution

cancer cell2023 Oct41(10)

1788-1802

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor diseasecancer cell2023 Jun41(6)1032-1047

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

blood adv

2023 Sep

7(18)5234-5245

Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial

blood adv

2023 Oct7(19)5996-6004

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

nature2023 Sep

621(7978)404-414

Genetic basis and molecular profiling in myeloproliferative neoplasms

blood2023 Apr

141(16)

1909-1921

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

leukemia2018 Jul32(7)1631-1642

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

JCO2018 Jun

36(17)

1769-1770

Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management

Am J Hematol

2018 Dec

93(12)

1551-1560

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

JCO

2023 Nov

41(32)

4993-5004

Nov
A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UKblood
NCRI AML18 Trial 2022
Results

140(sup1)

532-533

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

leukemia

2023 Nov

doi: 10.1038

s41375-023-02068-8

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

leukemia

2023 Dec

37(12)

2395-2403

What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?

JCO

2023 Oct41(29)

4693-4703

Genetic Determinants of Clonal Hematopoiesis and Progression to Hematologic Malignancies in 479,117 Individuals

blood

2023

142(sup1)

811

Plasma Proteomic Signature Predicts Risk of Myeloid Neoplasm

blood

2023

142(sup1)

940

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

blood

2023

142(sup1)

997

Genotype-Phenotype Mapping Via Single-Cell Multi-Omics Identifies Therapeutic Vulnerabilities in Vexas Syndrome

blood

2023

142(sup1)

813

Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome

blood

2023

142(sup1)

703

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia
blood(AML): Retrospective
2023 Analysis of
142(sup1)
an Electronic Medical
550 Record (EMR) Database in the United States
Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents
blood(HMA): A Multicenter,2023 Propensity142(sup1)
Score Analysis 321
古本
12/19 坂本加藤

1/16 山田

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of theJCO
Blood and Marrow
2023
Transplant
Oct
Clinical41(28)
Trials Network4497-4510
1102 Study
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving JCO
Chimeric
AntigenReceptor
T-CellTherapy
Minimal Residual
DiseaseStatus
Predicts
Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM
JCOStudy

2023 Oct

23 10972024 Feb42(5)550-561

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma
JCO Elderly Trial 2024 Feb

42(5)538-549

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

N Engl J Med

2024 Jan390(4)

326-337

Efficacy and safety of ruxolitinib in steroid-refractory graft- versus-host disease: A meta-analysis

Front Immunol

2022 Aug

4

13

Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis

Front Immunol

2022 Nov

11

13

安東
1/23 松本

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease

Transplant Cell Ther
2021 Mar

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

N Engl J Med

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Cancer Cell

27(3)

272

2020 May 382(19):1800-1810.
382(19)1800-1810

2023 Dec

2136-2153

41(12)

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow
Biol
Transplantation
Blood Marrow2016
andTransplant
Cell
FebTherapies22(2)240-247

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneicBMC
hematopoietic
Cancer stem
2023
cell
Aug
transplantation:23(1) a systematic764
review and meta-analysis

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry
Haematologica
analysis on 698
2018
patients
Feb by the103(2)Chronic Malignancies
237-245
Working Party of the European Society of Blood and Ma
クリクラ学生1/30 桐野

蓬莱
2/6 児嶋佐藤
2/20 坂本Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome
Cancer Sci

2021 Sep

112(9)

3636-3644

Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia

N Engl J Med

2023 Mar388(11)1032-1041

Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML

Blood Adv

2024 Jan8(2)343-352.

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Blood Adv

2022 Feb

6(3)882-890

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

JCO

2024 Jan

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational,
Lancetrandomised, 2024
double-blind,Jan
placebo-controlled,403(10423)
phase249-260
3 trialChronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

N Engl J Med

2024 Jan390(4)

326-337

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

Blood Adv

2023 Aug7(16)4291-4301

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

N Engl J Med

2023 Jan388(4)

319-332

Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells

Blood2024 Jan

143(1)

32-41

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

N Engl J Med

2016 Aug375(8)

740-53Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label,
Lancetrandomised,
Haematolphase20173AugINO-VATE study4(8)Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

Bone Marrow Transplan
2018 Apr

53(4)e387-e398
449-456

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cellHaematologica
transplantation and
2023
risk
Dec
of sinusoidal obstruction syndrome/venous occlusive disease
クリクラ学生3/19 桐野渡辺
4/2 児嶋安東

4/9 加藤糸永
4/16 クリクラ学生
蓬莱

4/23 山田
坂本

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

N Engl J Med

2024 Jan390(4)

301-313

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Blood Adv

2024 Feb

8(4)927-935

Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma

Blood Adv

2024 Jun

8(11)2601-2611

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma

Cancer Sci

2021 Jun112(6)

2426-2435

Correlation analysis between auto-immunological and mutational profiles in myelodysplastic syndromes

Inflamm Res

2023 Aug72(8)1695-1707

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers

Cancer Cell

2024 Apr

8;42(4)568-582

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Nature2017 Jul

547(7662)

222-226

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

Front Immunol

2021 Mar

9:12636568Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

Nat Med2024 Feb

30(2)507-518

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Blood

2023 Oct142(14)1208-1218

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Blood Adv

2020 Jul

14;4(13)3024-3033

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood2021 Dec

138(24)2499-2513

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Blood Adv

2024 Apr

23;8(8)1857-1868

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood

2023 Sep

142(10)865-877

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Blood Adv

2024 Apr

9;8(7)

639-1650

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

N Engl J Med

2023 Jun

388(25)2338-2348

Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation

Bone Marrow Transplant
2021 Jan56(1)129-136

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor

Bone Marrow Transplant2024 Mar59(3)344-349

移植学会の報告

Blood Cancer J
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/102024
HLAFebmatched unrelated
14(1) donors: final
31 analysis of a randomized, open-label, multicenter, phase 2
4/30 宮﨑佐藤

5/7 南野松本

5/14 田口T-cell dysfunctions in myelodysplastic syndromesBlood2024 Apr

143(14)1329-1343

Prognostic impact of CEBPA mutational subgroups in adult AML

Leukemia

2024 Feb

38(2)281-290

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

N Engl J Med

2024 Apr

390(16)1467-1480

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Blood

2023 Oct

5;142(14)1208-1218

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

Am J Hematol

2024 Apr

99(4)615-624

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

Leukemia

2019 Dec

33(12)

2795-2804

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Am J Hematol

2022 Nov

97(11)

E416-E419

Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)

Rinsho Ketsueki 202465(3)135-141

Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advancesBlood2023 Mar

141(13)1513-1523

Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome

Nat Commun

2021 Feb

12(1)

1334

糸永
5/21 クリクラ学生
渡辺

Somatic genetic rescue of a germline ribosome assembly defectNat Commun

2021 Aug

12(1)

5044

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers

Cancer Cell

2024 May42(5)850-868

Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set

Blood

2021 Nov

138(20)1917-1927

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Blood2017 Nov

23;1302243-2250

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings
Blood from the Phase2020 Nov
3, Randomized
136 REACH3(Supplement
Study
1)
22–24

5/4 研修医桐野
6/4 坂本加藤
6/18 学生
山田
7/2 勝岡安東
7/9 南野Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood

2021 Dec

138(22)2278-2289

Axatilimab for chronic graft-versus-host disease after of at least two prior systemic therapies: results of phase I/II study

J Clin Oncol

2023 Apr

41(10)

1864-1875

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

Elife2020 Nov

9e60470A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

Blood Adv

2024 May8(10)2342-2350

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

N Engl J Med

2024 Jan390(4)

326-337

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia
Lancet(ASAP):
Haematola randomised,2024 May open-label,
11(5)phase 3, non-inferiority
e324-e335trial
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasBlood2024 Mar

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

N Engl J Med

2024 May

143(13)1231-1241

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

JCO

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

N Engl J Med

2024 Mar

10;42(8)881-8852020 Oct

22;383(17)Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

1613-1623

N Engl J Med

2024 Jun

13;390(22)2074-2082

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia

N Engl J Med

2024 Jun

390(23)2178-2190

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers

Cancer Cell

2024 May42(5)850-868

Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone
Am J Hematol
de Greffe2021 deJulMoelle et96(7)de Thérapie Cellulaire834-845(SFGM-TC)
Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma

12832428

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation
Biol Blood Marrow2018
TransplantDec

24(12)

471-2478

佐藤Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes

Blood Adv

2024 May8(10)2442-2454

7/16 安東An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis

Cell2024 Jun

6;187(12)3090-3107

Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss

Cell2024 Jul

187(14)3690-3711

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary
JCO
Acute Myeloid
2018 Sep
Leukemia 36(26)2684-2692

クリクラ学生7/23 糸永田口

7/30 坂本

桐野

Front Oncol

2022 Feb 16

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of theTransplant
American
Cell
Society
Ther
2024forJul
Transplantation
6:S2666-6367(24)and Cellular0Therapy
0487-1 and the European Society for Blood and Marrow Tra
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

Nat MedReconstructing Complex Cancer Evolutionary Histories from Multiple Bulk DNA Samples Using Pairtree

Blood Cancer Discov
2022 May

2024 Juldoi: 10.1038/s41591-024-03084-6
3(3)208-219CALDER: Inferring Phylogenetic Trees from Longitudinal Tumor Samples

Cell Syst

2019 Jun

8(6)514-522

The implications of clonal genome evolution for cancer medicine

N Engl J Med

2013 Feb368(9)

842-51

Clonal evolution in leukemia

Nat Med2017 Oct23(10)

1135-1145

Cancer evolution: Darwin and beyond

EMBO J

2021 Sep

40(18)

e108389

SnapShot: Tumor evolution

Cell2021 Mar184(6)

1650-1650.e1

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Blood

2024 Jul

144(3)

323-333

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL

J Clin Oncol

2024 Jul

JCO2400272

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma(MARTA): a single-arm, phase 2 trial
Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Lancet Haematol 2024 Mar11(3)e196-e205

Blood neoplasia 2024 Sep

1 (3)

1 (3): 100022.